Gilead Sciences (GILD) Gets a Buy from TD Cowen
TD Cowen analyst Tyler Van Buren maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of ...
Hosted on MSN2h
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over ...
Multiple Catalysts Ahead For Nektar Therapeutics
Nektar continues to make progress with rezpegaldesleukin, with results from phase 2 atopic dermatitis study expected in H1'25 ...
Gilead Sciences to close Seattle office; shutdown impacts 72 employees
Biopharma giant Gilead Sciences will shut down its office in Seattle’s Eastlake neighborhood, the company confirmed to ...
Business Insider14h
Gilead Prices $3.5 Bln Of Senior Unsecured Notes
(RTTNews) - Gilead Sciences Inc. (GILD) announced the pricing of senior unsecured notes in an aggregate principal amount of $3.5 billion, in an underwritten, registered public offering, consisting of ...
Gilead reports positive HIV PrEP data for lenacapavir
Gilead (GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention treatment lenacapavir ...